The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 01, 2017

Filed:

May. 18, 2013
Applicant:

Georgia State University Research Foundation, Inc., Atlanta, GA (US);

Inventors:

Didier Merlin, Decatur, GA (US);

Bo Xiao, Decatur, GA (US);

Hamed Laroui, Decatur, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/50 (2006.01); A61K 47/48 (2006.01); C12N 15/11 (2006.01); A61B 5/00 (2006.01); A61K 31/713 (2006.01); A61K 39/395 (2006.01); A61K 49/00 (2006.01); C12N 15/113 (2010.01); C12N 15/88 (2006.01);
U.S. Cl.
CPC ...
A61K 9/5036 (2013.01); A61B 5/0071 (2013.01); A61B 5/4255 (2013.01); A61K 31/713 (2013.01); A61K 39/3955 (2013.01); A61K 47/482 (2013.01); A61K 47/48215 (2013.01); A61K 47/48507 (2013.01); A61K 47/48915 (2013.01); A61K 49/00 (2013.01); C12N 15/111 (2013.01); C12N 15/1136 (2013.01); C12N 15/88 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01);
Abstract

The present invention features, inter alia, constructs for the delivery of therapeutic and diagnostic agents to a patient. The constructs can include a nanoparticle, a targeting agent that specifically binds a targeted tissue or cell, a therapeutic moiety, and a hydrogel. The constructs can be used in the treatment and diagnosis of bowel diseases, including inflammatory bowel disease (IBD) and colon cancer. In one embodiment, the therapeutic agent is a nucleic acid that mediates RNA inhibition (RNAi), and the invention is directed to treatments for IBD that combine the positive aspects of such agents {e.g., siRNAs) with the safety of a biodegradable polymeric delivery system to facilitate specific targeting of colonic tissues and cells. As the constructs can be formulated for oral administration, they are well tolerated and offer advantages with regard to patient compliance.


Find Patent Forward Citations

Loading…